<DOC>
	<DOCNO>NCT00003626</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness dolastatin 10 treat patient metastatic prostate cancer respond previous hormone therapy .</brief_summary>
	<brief_title>Dolastatin 10 Treating Patients With Metastatic Prostate Cancer That Has Not Responded Previous Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient hormone refractory prostate cancer treat dolastatin 10 . II . Determine toxicity regimen patient population . OUTLINE : Patients receive dolastatin 10 IV bolus every 3 week . Treatment continue minimum 2 course absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : A total 15-30 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Dolastatin 10</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Hormone refractory metastatic prostate cancer ( stage D1 D2 ) great 3 prior endocrine manipulation PSA level increase 3 consecutive measurement least 2 week apart PSA least 10 ng/mL ( require measurable disease ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 02 Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 1,500/mm3 Hemoglobin least 8 g/dL Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2 mg/dL AST great 2 time upper limit normal Renal : Creatinine le 2.0 mg/dL Other : No serious medical illness No serious infection No prior malignancy within past 5 year except nonmelanoma skin cancer situ carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics Concurrent LHRHagonist therapy allow without antiandrogens At least 4 week since prior flutamide nilutamide At least 6 week since prior bicalutamide At least 4 week since prior hormone therapy include steroid Radiotherapy : At least 4 week since prior radiation therapy recover No prior strontium Surgery : Recovered prior surgery</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>